| 商品名称 | Venvia |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Diabetes Mellitus, Type 2 |
| 通用名/非专利名称 | rosiglitazone |
| 活性成分 | rosiglitazone |
| 产品号 | EMEA/H/C/000270 |
| 患者安全信息 | No |
| 许可状态 | Withdrawn |
| ATC编码 | A10BG02 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2000/07/11 |
| 上市许可开发者/申请人/持有人 | SmithKline Beecham Plc |
| 人用药物治疗学分组 | Drugs used in diabetes |
| 兽用药物治疗学分组 | |
| 欧盟委员会决定日期 | 2004/11/25 |
| 修订号 | 6 |
| 治疗适应症 | Rosiglitazone is indicated as oral monotherapy in type 2 diabetes mellitus patients, particularly overweight patients, inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. Rosiglitazone is also indicated for oral combination treatment in type 2 diabetes mellitus patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea: in combination with metformin particularly in overweight patients. in combination with a sulphonylurea only in patients who show intolerance to metformin or for whom metformin is contraindicated. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2004/11/25 |
| 最后更新日期 | 2005/04/18 |
| 产品说明书 | |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/venvia |